The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its future within the broader market now presents questions about long-term returns . Generic versions are eroding exclusivity , prompting worries that betting on companies heavily reliant to Viagra's once-dominant standing could be a speculative